Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to -$0.3.

  • Autolus Therapeutics' EPS (Weighted Average and Diluted) rose 322.58% to -$0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.83, marking a year-over-year increase of 3196.72%. This contributed to the annual value of -$0.86 for FY2024, which is 2793.37% up from last year.
  • Latest data reveals that Autolus Therapeutics reported EPS (Weighted Average and Diluted) of -$0.3 as of Q3 2025, which was up 322.58% from -$0.18 recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.53 during Q1 2021, and its lowest value of -$466.29 during Q3 2021.
  • For the 5-year period, Autolus Therapeutics' EPS (Weighted Average and Diluted) averaged around -$24.9, with its median value being -$0.26 (2023).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 10000.18% in 2021, then tumbled by 19787.23% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' EPS (Weighted Average and Diluted) stood at -$3.43 in 2021, then surged by 93.29% to -$0.23 in 2022, then tumbled by 95.65% to -$0.45 in 2023, then surged by 75.96% to -$0.11 in 2024, then tumbled by 177.29% to -$0.3 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.3 in Q3 2025, compared to -$0.18 in Q2 2025 and -$0.26 in Q1 2025.